Vital Therapies (VTL) Releases Earnings Results, Misses Estimates By $0.04 EPS

Vital Therapies (NASDAQ:VTL) announced its quarterly earnings data on Tuesday. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04), Bloomberg Earnings reports. During the same quarter in the prior year, the company earned ($0.37) EPS.

Shares of Vital Therapies (NASDAQ:VTL) traded down $0.20 during mid-day trading on Tuesday, hitting $5.60. 85,172 shares of the company traded hands, compared to its average volume of 171,430. The company has a market cap of $249.02, a P/E ratio of -4.15 and a beta of 4.63. Vital Therapies has a 1-year low of $2.25 and a 1-year high of $6.70.

In related news, Director Muneer A. Satter bought 100,000 shares of Vital Therapies stock in a transaction that occurred on Wednesday, December 13th. The stock was acquired at an average price of $5.48 per share, with a total value of $548,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 32.60% of the company’s stock.

VTL has been the subject of several research analyst reports. Raymond James Financial reaffirmed a “buy” rating on shares of Vital Therapies in a report on Tuesday, December 5th. ValuEngine downgraded shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a report on Friday, November 17th. Finally, BidaskClub raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st.

WARNING: This report was first published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Earnings History for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with's FREE daily email newsletter.

Leave a Reply